The study of efficacy and complications of uterine artery embolization in patients with symptomatic uterine fibroids

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2014012714333N16

Enrollment

Registered

2014-02-12

Start date

2013-09-11

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

utrine fibroids and bleeding. Other specified noninflammatory disorders of uterus

Interventions

In the study group , a catheter enters into the common femoral artery through a small incision on the skin of the groin and is placed in the distal of uterine artery where the artery is became transve

Treatment - Surgery

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Inclusion criteria: written consent of the patient; women with symptomatic uterine fibroids; candidate of hysterectomy or myomectomy. Exclusion criteria: no menopause, ovarian tumors.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Type of fibroids. Timepoint: Baseline and 3, 6 and 12 months after embolization (UAE). Method of measurement: MRI.;Uterine size. Timepoint: Baseline and 3, 6 and 12 months after embolization (UAE). Method of measurement: Sonography.;Clinical symptoms. Timepoint: 3, 6 and 12 months after embolization (UAE). Method of measurement: Based on questionnaire.;Fibroid size. Timepoint: Baseline and 3, 6 and 12 months after embolization (UAE). Method of measurement: MRI.;Permanent amenorrhea. Timepoint: Baseline and 3, 6 and 12 months after embolization (UAE). Method of measurement: Asking the patient.;Continuous vaginal discharge. Timepoint: 3, 6 and 12 months after embolization (UAE). Method of measurement: Asking the patient.;Recurrence of fibroids. Timepoint: 3, 6 and 12 months after embolization (UAE). Method of measurement: MRI.	—

Measure

Time frame

Type of fibroids. Timepoint: Baseline and 3, 6 and 12 months after embolization (UAE). Method of measurement: MRI.;Uterine size. Timepoint: Baseline and 3, 6 and 12 months after embolization (UAE). Method of measurement: Sonography.;Clinical symptoms. Timepoint: 3, 6 and 12 months after embolization (UAE). Method of measurement: Based on questionnaire.;Fibroid size. Timepoint: Baseline and 3, 6 and 12 months after embolization (UAE). Method of measurement: MRI.;Permanent amenorrhea. Timepoint: Baseline and 3, 6 and 12 months after embolization (UAE). Method of measurement: Asking the patient.;Continuous vaginal discharge. Timepoint: 3, 6 and 12 months after embolization (UAE). Method of measurement: Asking the patient.;Recurrence of fibroids. Timepoint: 3, 6 and 12 months after embolization (UAE). Method of measurement: MRI.

—

Countries

Iran (Islamic Republic of)

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026